Moreover, the treatment of PAMs with the recombinantly expressed CD163 SRCR1-4 could significantly inhibit both PRRSV-1 and PRRSV-2 infections via competitive binding for MYH9 with the endogenous CD163. This evidence concerns the gene CD163 and infection.